Efficacy and Safety Study of MYOBLOC® in the Treatment of Sialorrhea in Adult Subjects

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 187 participants.

Also called NCT01994109

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 187 participants (enrolled count) (from the registry)
Sponsor
Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC (from the registry)
Registry
  • NCT NCT01994109
Other papers using this trial's data
  • Safety and Efficacy of RimabotulinumtoxinB for Treatment of Sialorrhea in Adults: A Randomized Clinical Trial JAMA neurology, 2020-04-01 DOI, PubMed 31930364, PMC6990829 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Russia, Ukraine (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01994109. Randomized; quadruple masking; primary purpose treatment. Start 2013-11 (registry gives no type); primary completion 2016-01 (actual). Results posted on 2019-08-15.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety Study of MYOBLOC® in the Treatment of Sialorrhea in Adult Subjects
Acronym
MYSTICOL
Condition
Sialorrhea
Intervention (Drug)
MYOBLOC
Intervention (Other)
PLACEBO
Lead sponsor
Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC (class: industry)

Record details

Record id
cardio:ct-nct01994109
Content hash
07d36a1a902dbf1b8069aed1157d25e894eb43326fab4c697d12366eb2d3f1b3